Parabilis Medicines News and Activities

Parabilis Medicines is a company listed under the stock ticker PBLS (US).

Acquisition, funding and merger involving Parabilis Medicines.

• Parabilis Medicines has just announced a $670 Million fundraising (posted on June 11 2026).
• Parabilis Medicines has filed its IPO. Its stock ticker will be PBLS. (posted on May 20 2026).
• Parabilis Medicines has just announced a $305 Million fundraising (posted on January 8 2026).

View the org chart displaying its 38 main executives

Most searched biographies at Parabilis Medicines

• Mathai Mammen, Chairman of the Board, President and Chief Executiv...
• Edward Fitzgerald, Director
• Alan Sebulsky, Director

Popular executive movements at Parabilis Medicines

• Mark Ator, Associate Vice President, Discovery Drug Metabolism and Pharmacokinetics, has left the company  (posted on May 20 2026).
• Brandon Allgood, Chief Data Science Officer, has left the company  (posted on May 20 2026).
• Alan Sebulsky has joined the company as Director  (posted on May 8 2026).

Click here to view some more movements at Parabilis Medicines

Create your alert
to follow the executive moves at Parabilis Medicines.

Parabilis Medicines has 1,920 competitors including Sanofi (France), Moderna (United States (USA)) and Eli Lilly (United States (USA)).

Popular M&A news in Pharmaceuticals

• Catalyst Pharmaceuticals, listed under ticker CPRX, has been delisted. (posted on July 13 2026).
• Angelini Pharma has acquired Catalyst Pharmaceuticals (posted on July 13 2026).
• Vertex Pharmaceuticals has announced the acquisition of Crinetics Pharmaceuticals  (posted on July 7 2026).

Popular contacts in Pharmaceuticals

• David Ricks - President, Chief Executive Officer and Chairman of the Board at Eli Lilly
• Richard Saynor - Chief Executive Officer at Sandoz
• Joaquin Duato - Chief Executive Officer and Chairman of the Board at Johnson & Johnson

Learn more about the Pharmaceuticals industry

Press releases by Parabilis Medicines

• Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares - Thu, 06/11/2026 - 16:05
• News Releases - Parabilis Medicines
• Events - Parabilis Medicines
• Parabilis Medicines Announces Pricing of Upsized Initial Public Offering - Tue, 06/09/2026 - 20:22
• Presentations - Parabilis Medicines
• Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas - Parabilis Medicines
• Parabilis Medicines Announces Strategic Collaboration with Regeneron Pharmaceuticals to Advance Novel Antibody-Helicon™ Conjugates Across Multiple Therapeutic Areas - Parabilis Medicines
• Parabilis Medicines Appoints Biopharmaceutical Finance Leader Alan M. Sebulsky to Board of Directors - Parabilis Medicines
• Parabilis Medicines Expands Executive Leadership Team - Parabilis Medicines
• Parabilis Medicines’ Zolucatetide, the First and Only Direct Inhibitor of the Elusive β-catenin:TCF Interaction, Receives FDA Orphan Drug Designation for the Treatment of Desmoid Tumors - Parabilis Medicines
• View more press releases Close

Social media about Parabilis Medicines

• Parabilis Medicines on Wikipedia, Google News & Yahoo Finance
• Parabilis Medicines on LinkedIn, X (Twitter) & YouTube